Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept of Onc
mi
from
Columbus, OH
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept of Onc
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute SCRI SC
mi
from
Nashville, TN
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute SCRI SC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center SC-5
mi
from
Nashville, TN
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center SC-5
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Utah / Huntsman Cancer Institute Onc Dept
mi
from
Salt Lake City, UT
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Utah / Huntsman Cancer Institute Onc Dept
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Array BioPharma Investigative Site
mi
from
Parkville,
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Array BioPharma Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
HonorHealth
mi
from
Scottsdale, AZ
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
HonorHealth
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
University of Michighan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
University of Michighan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated:  12/31/1969
Deaconess Hospital
mi
from
Spokane, WA
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated: 12/31/1969
Deaconess Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated:  12/31/1969
Sacred Heart Medical Center
mi
from
Spokane, WA
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated: 12/31/1969
Sacred Heart Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated:  12/31/1969
Holy Family Hospital
mi
from
Spokane, WA
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated: 12/31/1969
Holy Family Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated:  12/31/1969
Valley Hospital
mi
from
Spokane, WA
The Inland Northwest Colon Cancer Survivor's Study
Self Reported Changes in Quality of Life, Demands of Illness, and Sexual Function in Colon Cancer Survivors.
Status: Enrolling
Updated: 12/31/1969
Valley Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
USOR - Minnesota Oncology Hematology
mi
from
Minneapolis, MN
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
USOR - Minnesota Oncology Hematology
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Institute for Translational Oncology Research, Greenville Hospital System
mi
from
Greenville, SC
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Institute for Translational Oncology Research, Greenville Hospital System
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
USOR - Texas Oncology Dallas
mi
from
Dallas, TX
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
USOR - Texas Oncology Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
US Oncology Research
mi
from
The Woodlands, TX
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
US Oncology Research
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
USOR - Texas Oncology, Tyler
mi
from
Tyler, TX
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
USOR - Texas Oncology, Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
USOR - Virginia Cancer Specialists
mi
from
Fairfax, VA
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
USOR - Virginia Cancer Specialists
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
USOR - Rocky Mountain Cancer Center
mi
from
Denver, CO
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
USOR - Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
USOR - Northwest Cancer Specialists
mi
from
Portland, OR
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
USOR - Northwest Cancer Specialists
mi
from
Portland, OR
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ogden, UT
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Szczecin,
Open Label Extension Study of Conatumumab and AMG 479
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Szczecin,
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Santa Monica, CA
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
Helen F Graham Cancer Center/ Christiana Care
mi
from
Newark, DE
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
Helen F Graham Cancer Center/ Christiana Care
mi
from
Newark, DE
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
IUHealth Goshen Center for Cancer Care
mi
from
Goshen, IN
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
IUHealth Goshen Center for Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
Fox Chase
mi
from
Philadelphia, PA
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
Fox Chase
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Scottsdale, AZ
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials